Pharmaceutical composition for treating osteoporosis, liposome preparation of pharmaceutical composition, and preparation method thereof

A technology for osteoporosis and composition, which is applied in the field of pharmaceutical composition for treating osteoporosis and its liposome preparation and preparation, can solve the problem that calcium preparation cannot be effectively absorbed and utilized, slow-release effect is not good, stable The problem of poor sexuality, etc., to achieve exact therapeutic effect, moderate effect, and small side effects.

Inactive Publication Date: 2015-09-09
SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Fluoride in drugs that promote bone formation can easily induce bone hypomineralization and lead to osteomalacia, and a large amount of fluorine intake can cause many serious diseases in the body, so it must be used with caution. Gallium nitrate has nephrotoxicity
Calcium preparations in drugs that promote bone mineralization cannot be effectively absorbed and utilized by the body
[0004] In addition to the above-mentioned defects, traditional pharmaceutical preparations also have the disadvantages of poor stability and poor sustained-release effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating osteoporosis, liposome preparation of pharmaceutical composition, and preparation method thereof
  • Pharmaceutical composition for treating osteoporosis, liposome preparation of pharmaceutical composition, and preparation method thereof
  • Pharmaceutical composition for treating osteoporosis, liposome preparation of pharmaceutical composition, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] One embodiment of the present invention provides a method for preparing liposome preparations, comprising: dissolving 10-100 parts by mass of egg yolk lecithin and cholesterol in a mixed solvent of chloroform and methanol, wherein the above-mentioned egg yolk lecithin and cholesterol The mass ratio is 2:1-6:1; then the chloroform and methanol are evaporated under reduced pressure to form a uniform lipid film; 1-5 mass parts of icariin, 1-5 mass parts of glycosides, 1 -5 parts by mass of loganin are dissolved in phosphate buffer, and then the buffer is added to the above lipid film as the water phase, and then several beads are added to shake until the film falls off completely, and then placed in a water bath at 20-80°C Swell in medium for 5-30min, then stir at a constant speed for 5-30min, ultrasonicate in an ice bath for 5-60min to obtain a liposome suspension, and then squeeze the above liposome suspension through a microporous membrane , to obtain liposome preparati...

Embodiment 1

[0049] The liposome preparation of this embodiment is prepared by thin film dispersion method. Dissolve 4 g of yolk lecithin and cholesterol for injection (W / W, 4:1) in an appropriate amount of chloroform and methanol (V / V, 1:1), and then use a rotary evaporator to evaporate under reduced pressure to remove chloroform and methanol to make the lipid The substance forms a uniform lipid film on the wall of the pear-shaped bottle; weigh 0.3g icariin, 0.3g and loganin 0.3g and dissolve them in a phosphate buffer (10mL) with a pH of 7.2, and then The buffer solution (10 mL) was added to the lipid film as the water phase, and then ten glass beads (5 mm in diameter) were added, oscillated until the film fell off completely, swelled in a water bath at 40°C for 10 min, and then stirred at a constant speed for 10 min. Sonicate in the bath for 30 minutes to obtain a liposome suspension, and then squeeze it through microporous membranes with pore diameters of 0.80 micron, 0.45 micron, and ...

Embodiment 2

[0051] The liposome preparation of this embodiment is prepared by thin film dispersion method. Dissolve 3 g of egg yolk lecithin for injection and cholesterol (W / W, 2:1) in an appropriate amount of chloroform and methanol (V / V, 3:1), and then use a rotary evaporator to evaporate under reduced pressure to remove chloroform and methanol to make the lipid The substance forms a uniform lipid film on the wall of the pear-shaped bottle; Weigh 0.1g of icariin, 0.1g of icaritin and 0.1g of loganin and dissolve it in a phosphate buffer (5mL) with a pH of 7.2, and then The buffer solution (5 mL) was added to the lipid film as the water phase, and then ten glass beads (particle diameter: 2 mm) were added, oscillated until the film fell off completely, swelled in a water bath at 80°C for 5 min, and then stirred at a constant speed for 5 min. Sonicate in the bath for 60 minutes to obtain a liposome suspension, which is then squeezed through microporous membranes with pore diameters of 0.80...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating osteoporosis, a liposome preparation of the pharmaceutical composition, and a preparation method thereof. The pharmaceutical composition comprises the following components in mass part: 1-5 parts of icaritin, 1-5 parts of chiratin, 1-5 parts of loganin and an optional pharmaceutically acceptable carrier. According to the technical scheme of the invention, icaritin, chiratin and loganin are adopted as active pharmaceutical ingredients to be combined for the first time. It has been proved that, the pharmaceutical composition has an outstanding curative effects in treating osteoporosis. Meanwhile, based on the characteristics of traditional Chinese medicine, the pharmaceutical composition has the obvious advantages of moderate effect and little side effects. The pharmaceutical composition is prepared in the form of a liposome preparation, thus being good in targeting and obvious in sustained-release effect. The liposome preparation well reduces the toxic effect of the pharmaceutical composition and improves the stability of the pharmaceutical composition.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating osteoporosis, a liposome preparation and a preparation method thereof. Background technique [0002] In postmenopausal women, due to the degeneration of ovarian function, the levels of various hormones secreted by the ovary decrease, the bone microstructure changes, and the risk of bone fragility increases, leading to the occurrence of osteoporosis. Osteoporosis is one of the most destructive diseases of the skeletal and muscular systems, increasing the risk of fractures that worsen with age. Osteoporosis does not show obvious clinical symptoms in the early stage, and is vividly called a "silent killer". If prevention and treatment are not carried out as soon as possible, it is often too late when the patient has obvious clinical symptoms such as bone pain , and bring huge physical and psychological harm to patients. If the patient ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K9/127A61P19/10A61K31/352
Inventor 王琳瑛王新峦曹会娟秦岭
Owner SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products